WHNT

Thea Pharma Inc. Launches IYUZEH™ (latanoprost ophthalmic solution) 0.005% in the U.S.

Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9200651-thea-pharma-inc-launches-iyuzeh/ "The U.S. launch of ...
Nasdaq

Glenmark Pharmaceuticals Launches Latanoprost Ophthalmic Solution In The U.S.

(RTTNews) - Glenmark Pharmaceuticals Ltd. (GLENMARK.NS), Friday announced that it has introduced Latanoprost Ophthalmic Solution, 0.005 percent, a bioequivalent and therapeutically equivalent ...
Business Wire

Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda ® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Marketing Authorisation Application in Europe

Aerie’s first product, Rhopressa ® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular ...
Healio

TearClear initiates phase 3 trial of preservative-free latanoprost

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio TearClear has initiated a phase 3 trial ...
Business Wire

Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 12-month Topline Safety Results

IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ...